OBJECTIVE: To assess the plasma Pentraxin 3 (PTX3) concentrations in obese children and to investigate the relationship between PTX3 levels and metabolic syndrome (MS) components. METHODS: Seventy-seven obese patients aged 10-16 y (38 girls, 39 boys) were included in the study. PTX3 levels were compared between the groups with or without MS. In addition, PTX3 was analysed separately by subgroups according to the presence of specific MS components. RESULTS: Plasma PTX3 concentrations were significantly higher in obese children and adolescents with metabolic syndrome than in those without MS (2.1 ± 1.2 ng/ml and 1.4 ± 0.9 ng/ml respectively; P = 0.02). Patients with low HDL levels (<40 mg/dl) had higher plasma PTX3 concentrations than those with normal HDL levels (P = 0.05). Similarly, those who had high triglyceride levels (≥ 150 mg/dl) had higher PTX3 levels (P = 0.01). PTX3 levels were negatively correlated with HDL cholesterol (r = -0.32, P = 0.003) among all patients. CONCLUSIONS: PTX3 levels are higher in obese children and adolescents with metabolic syndrome than in those without MS. Thus, PTX3 levels might be a useful biomarker for children and adolescents with metabolic syndrome, dyslipidemia, and cardiovascular risks.
OBJECTIVE: To assess the plasma Pentraxin 3 (PTX3) concentrations in obesechildren and to investigate the relationship between PTX3 levels and metabolic syndrome (MS) components. METHODS: Seventy-seven obesepatients aged 10-16 y (38 girls, 39 boys) were included in the study. PTX3 levels were compared between the groups with or without MS. In addition, PTX3 was analysed separately by subgroups according to the presence of specific MS components. RESULTS: Plasma PTX3 concentrations were significantly higher in obesechildren and adolescents with metabolic syndrome than in those without MS (2.1 ± 1.2 ng/ml and 1.4 ± 0.9 ng/ml respectively; P = 0.02). Patients with low HDL levels (<40 mg/dl) had higher plasma PTX3 concentrations than those with normal HDL levels (P = 0.05). Similarly, those who had high triglyceride levels (≥ 150 mg/dl) had higher PTX3 levels (P = 0.01). PTX3 levels were negatively correlated with HDL cholesterol (r = -0.32, P = 0.003) among all patients. CONCLUSIONS:PTX3 levels are higher in obesechildren and adolescents with metabolic syndrome than in those without MS. Thus, PTX3 levels might be a useful biomarker for children and adolescents with metabolic syndrome, dyslipidemia, and cardiovascular risks.
Authors: Anna Witasp; Juan Jesús Carrero; Karl Michaëlsson; Håkan Ahlström; Joel Kullberg; Viola Adamsson; Ulf Risérus; Anders Larsson; Johanna Helmersson-Karlqvist; Lars Lind; Peter Stenvinkel; Johan Arnlöv Journal: Obesity (Silver Spring) Date: 2014-01-25 Impact factor: 5.002
Authors: Alberto Mantovani; Cecilia Garlanda; Barbara Bottazzi; Giuseppe Peri; Andrea Doni; Yeny Martinez de la Torre; Roberto Latini Journal: Vascul Pharmacol Date: 2006-08-23 Impact factor: 5.773
Authors: O Osorio-Conles; M Guitart; M R Chacón; E Maymo-Masip; J M Moreno-Navarrete; M Montori-Grau; S Näf; J M Fernandez-Real; J Vendrell; A M Gómez-Foix Journal: Am J Physiol Endocrinol Metab Date: 2011-09-06 Impact factor: 4.310
Authors: Mehmet Fatih Karakas; Eyup Buyukkaya; Mustafa Kurt; Sedat Motor; Adnan Burak Akcay; Esra Karakas; Şule Buyukkaya; Nihat Sen Journal: Med Princ Pract Date: 2012-11-08 Impact factor: 1.927